Cargando…

A Review of Bullous Dermatologic Adverse Events Associated with Anti-Cancer Therapy

The rapid evolution of anti-cancer therapy (including chemotherapy, targeted therapy, and immunotherapy) in recent years has led to a more favorable efficacy and safety profile for a growing cancer population, and the improvement of overall survival and reduction of morbidity for many cancers. Anti-...

Descripción completa

Detalles Bibliográficos
Autores principales:	Parisi, Rose, Shah, Hemali, Shear, Neil H., Ziv, Michael, Markova, Alina, Dodiuk-Gad, Roni P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9953054/ https://www.ncbi.nlm.nih.gov/pubmed/36830860 http://dx.doi.org/10.3390/biomedicines11020323

Ejemplares similares

Acute Generalized Exanthematous Pustulosis: Clinical Features, Differential Diagnosis, and Management
por: Parisi, Rose, et al.
Publicado: (2023)

Adverse Medication Reactions
por: Dodiuk-Gad, Roni P., et al.
Publicado: (2017)

Drug Reaction with Eosinophilia and Systemic Symptoms (DReSS)/Drug-Induced Hypersensitivity Syndrome (DiHS)—Readdressing the DReSS
por: Stirton, Hannah, et al.
Publicado: (2022)

High Grade Dermatologic Adverse Events Associated With Immune Checkpoint Blockade for Cancer
por: Kuo, Alyce M., et al.
Publicado: (2022)

Risks of hydroxychloroquine use for COVID-19 prophylaxis
por: Sachdeva, Muskaan, et al.
Publicado: (2020)

Eponymous Dermatological Signs in Bullous Dermatoses
por: Ganapati, Sentamilselvi
Publicado: (2014)

COVID-19 and racial disparities
por: Shah, Monica, et al.
Publicado: (2020)

LEPOARD syndrome: A report of a case with a novel PTPN11 mutation
por: Rahal, Nader, et al.
Publicado: (2021)

Safety of Immunomodulatory Systemic Therapies Used in the Management of Immune-Related Cutaneous Adverse Events
por: Gu, Stephanie L., et al.
Publicado: (2023)

Cutaneous manifestations of COVID-19: Report of three cases and a review of literature
por: Sachdeva, Muskaan, et al.
Publicado: (2020)

Exploring a multi-disciplinary model of supportive cancer care for monoclonal antibody treatment-related dermatological symptoms
por: Kruger, Dikla, et al.
Publicado: (2023)

Toxic epidermal necrolysis–like dermatomyositis associated with antimelanoma differentiation antigen 5
por: Kushnir-Grinbaum, Daniella, et al.
Publicado: (2018)

Clinical and histopathological study of skin dermatoses in patients affected by COVID-19 infection in the Northern part of Italy
por: Gianotti, Raffaele, et al.
Publicado: (2020)

A Late Dermatologic Presentation of Bullous Pemphigoid Induced by Anti-PD-1 Therapy and Associated with Unexplained Neurological Disorder
por: Wang, Xiaoxiao, et al.
Publicado: (2021)

Management of dermatologic adverse events from cancer therapies: recommendations of an expert panel()()
por: Cury-Martins, Jade, et al.
Publicado: (2020)

Consensus on the treatment of autoimmune bullous dermatoses: dermatitis herpetiformis and linear IgA bullous dermatosis - Brazilian Society of Dermatology
por: do Vale, Everton Carlos Siviero, et al.
Publicado: (2019)

Bullous pemphigoid and neurological disease: statistics from a dermatology service()
por: Tarazona, Monica Jidid Mateus, et al.
Publicado: (2015)

Management of immune checkpoint inhibitor‐related dermatologic adverse events
por: Si, Xiaoyan, et al.
Publicado: (2019)

Consensus on the treatment of autoimmune bullous dermatoses: bullous pemphigoid, mucous membrane pemphigoid and epidermolysis bullosa acquisita - Brazilian Society of Dermatology
por: Santi, Claudia Giuli, et al.
Publicado: (2019)

Patient voice on management of facial dermatological adverse events with targeted therapies: a qualitative study
por: Yagasaki, Kaori, et al.
Publicado: (2019)

Activated Lymphocytes and Increased Risk of Dermatologic Adverse Events during Sorafenib Therapy for Hepatocellular Carcinoma
por: Corominas, Josep, et al.
Publicado: (2021)

Bullous Skin Rash: A Rare Case of Palbociclib-Induced Dermatological Toxicity
por: Khan, Noman Ahmed Jang, et al.
Publicado: (2020)

Preface to The Journal of Dermatology special issue: What's new in autoimmune bullous diseases
por: Tsuruta, Daisuke
Publicado: (2023)

Dermatologic immune-related adverse events: The toxicity spectrum and recommendations for management
por: Apalla, Zoe, et al.
Publicado: (2021)

Retrospective Analysis of Checkpoint Inhibitor Therapy-Associated Cases of Bullous Pemphigoid From Six German Dermatology Centers
por: Sadik, Christian D., et al.
Publicado: (2021)

SNG100, a novel topical treatment for moderate atopic dermatitis, in patients aged 6 years or older: A randomised, double‐blind, active‐controlled trial
por: Samuelov, Liat, et al.
Publicado: (2023)

Ectopic Cushing's syndrome in a patient with metastatic Merkel cell carcinoma: A case report
por: Ishay, Avraham, et al.
Publicado: (2022)

Bullous Pemphigoid and Diabetes medications: A disproportionality analysis based on the FDA Adverse Event Reporting System
por: Huang, Liting, et al.
Publicado: (2021)

Expert guidance on prophylaxis and treatment of dermatologic adverse events with Tumor Treating Fields (TTFields) therapy in the thoracic region
por: Anadkat, Milan J., et al.
Publicado: (2023)

Consensus on the treatment of autoimmune bullous dermatoses: pemphigus vulgaris and pemphigus foliaceus - Brazilian Society of Dermatology
por: Porro, Adriana Maria, et al.
Publicado: (2019)

Supporting Virtual Dermatology Consultation in the Setting of COVID-19
por: Kutner, Allison, et al.
Publicado: (2021)

Bullous Pemphigoid Complicated by Sepsis
por: Shah, Dipal, et al.
Publicado: (2022)

Prevention and Management of Dermatologic Adverse Events Associated With Tumor Treating Fields in Patients With Glioblastoma
por: Lacouture, Mario E., et al.
Publicado: (2020)

“Skin rashes” and immunotherapy in melanoma: distinct dermatologic adverse events and implications for therapeutic management
por: Sollena, Pietro, et al.
Publicado: (2021)

Bullous Pemphigoid as an Adverse Reaction to Pembrolizumab: Two Case Reports
por: Thomsen, Kenneth, et al.
Publicado: (2018)

Therapy of autoimmune bullous diseases
por: Mutasim, Diya F
Publicado: (2007)

Advanced Care Provider and Nursing Approach to Assessment and Management of Immunotherapy-Related Dermatologic Adverse Events
por: Ciccolini, Kathryn, et al.
Publicado: (2017)

Retrospective analysis of dermatologic adverse events associated with hydroxychloroquine reported to the US Food and Drug Administration
por: Lipner, Shari R., et al.
Publicado: (2020)

NQPC-9 CHARACTERIZATION AND MANAGEMENT OF DERMATOLOGIC ADVERSE EVENTS WITH OPTUNE® IN WAKAYAMA MEDICAL UNIVERSITY HOSPITAL
por: Fukai, Junya, et al.
Publicado: (2022)

Differential Dermatologic Adverse Events Associated With Checkpoint Inhibitor Monotherapy and Combination Therapy: A Meta-Analysis of Randomized Control Trials
por: Ge, Yang, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_i5cdnm8se5b9fk7qeqkfftud9j